Inhibiting PTEN activity in breast cancer resulted in CPVL promoting resistance to CDK4/6 inhibitors, and CPVL knockdown decreased the tumorigenicity of CDK4/6 inhibitor‐resistant cells in mice. The gene discussed is CDK4; the disease is breast cancer.